Business Context and Reporting Period
Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2026
Reporting Period: Event date April 22, 2026; Signed April 24, 2026.
This filing reports corporate governance amendments approved by the Board of Directors regarding the Company's Bylaws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The Board of Directors amended the Company's Bylaws on April 22, 2026, with the following specific changes:
- Director Removal (Section 2.5): Directors may now be removed from office at any time, with or without cause, by the holders of a majority of the shares entitled to vote at a director election.
- Stockholder Action Requirements (Section 1.12): Clarified that any action required or permitted to be taken at an annual or special meeting of stockholders may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the description of the Bylaw amendments and the listing of exhibits.
Key Facts for Investor Verification
- Verify the full text of the amended Bylaws attached as Exhibit 3.1 to understand the precise legal language of the changes.
- Confirm the impact of the new "with or without cause" removal provision on current Board stability and shareholder rights.
- Review the Company's Certificate of Incorporation (Article FIFTH) to ensure the Bylaw amendment regarding stockholder meetings is fully consistent with the charter.